Low-grade glioma – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Low-grade gliomas grade II astrocytomas, oligodendrogliomas, and oligoastrocytomas) are a diverse set of primary brain tumors that are characteristically diffuse and slow growing. Pediatric Low-grade gliomas (pLGG) are relatively slow-growing infiltrative primary brain tumors that almost invariably undergo malignant transformation most common brain tumours in children and can arise from glial cells, neuronal cells or both. This heterogeneity is also reflected in the diverse range of anatomical locations of these tumours within the CNS and in treatment outcomes, especially if surgical resection is either incomplete or not feasible.

Low-grade gliomas comprise several subgroups, including pilocytic, pilomyxoid, subependymal giant cell, and diffuse astrocytomas. 

Two cancer-predisposition syndromes, neurofibromatosis type 1 (NF1) and tuberous sclerosis complex, are associated with an increased frequency of pilocytic astrocytomas and subependymal giant cell astrocytomas, respectively.

Epidemiology-

According to literature survey, The annual incidence of pediatric 

LGGs is 1.5 to 2.35 per 100,000 in the US, estimated to be ~1,550 to 1,950 new diagnoses in 2019. Adult LGG is more common and is estimated to occur at a rate of 9.5 to 13.2 cases per 100,000 individuals in the US; and accounted for ~5,750 new diagnoses in 2019

 

The competitive landscape of Low-grade glioma includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Low-grade glioma across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Low-grade glioma Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Low-grade glioma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset                           Company                                 Stage

1          GAA/TT-peptide vaccine            Oncovir, Inc.     Early Phase 1

2          AG-120 and AG881       Agios Pharmaceuticals, Inc.       Phase 1

3          IMA950             Celldex Therapeutics     Phase 1

4          TAK-580           Millennium Pharmaceuticals, Inc.           Phase 1

5          PARP Inhibitor BGB-290            BeiGene USA, Inc.        Phase 1

6          Afatinib Boehringer Ingelheim     Phase 1

7          Mirdametinib     SpringWorks Therapeutics, Inc. Phase 2

8          Mebendazole    Janssen Pharmaceuticals          Phase 2

9          Trametinib and Dabrafenib         Novartis            Phase 2

10        DAY101            Day One Biopharmaceuticals, Inc.          Phase 2

Continue..